SRPTSarepta Therapeutics, Inc.
$17.85+2.4% 1Y
$17.85
$15.0052 weeks$24.45
The financials
Sarepta Therapeutics, Inc. by the numbers
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $401M in Q2 2026 (quarter ended Jun 30, 2026), down 34% from the same quarter a year earlier. That came with net loss of $4.9M. For the full year FY2025, revenue was $2.20B (+16% year on year) and net income −$713M. Its largest region in Q2 2026 was United States at $199M, 86% of the disclosed total, well ahead of Non Us at 14%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $401M | $611M | −34% |
| Gross profit | n/a | $361M | n/a |
| Operating income | $13M | $116M | −89% |
| Net income | −$4.9M | $197M | to a loss |
| Diluted EPS | −$0.05 | $1.89 | to a loss |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $199M | 86% |
| Non Us | $32M | 14% |
Business segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Jun 2026Total $230.6M (+0.88%)
Non Us grew +13% year on yearUnited States -2.1% year on year
Segment Latestquarter on quarteryear on year
- United States$198.6M$198.6Mquarter on quarter +5.2%year on year -2.1%+5.2%-2.1%
- Non Us$32.0M$32.0Mquarter on quarter -20%year on year +13%-20%+13%
On our screens:Most shorted stocks